SignalXSignalX

ENOV Enovis CORP

FY2025 10-K
Filed: Feb 26, 2026
Health Care
Orthopedic, Prosthetic & Surgical Appliances & SuppliesSEC EDGAR
Enovis CORP Overview

Enovis CORP (ENOV) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business model: Orthopedic solutions via two segments—Prevention & Recovery (P&R) and Reconstructive (Recon) with global manufacturing and sales
  • • New emphasis on Recon segment growth via $865.6M Lima acquisition in Jan 2024, adding digital innovation and customized hardware
+3 more insights

Management Discussion & Analysis

  • • Revenue $2.248B, up 5.1% YoY: P&R $1.137B (+$39M), Recon $1.111B (+$101.4M)
  • • Operating loss margin worsened: P&R (32.9)% vs (29.3)%, Recon (67.5)% vs (45.0)% in 2024 due to goodwill impairments ($387.8M P&R, $662M Recon)
+3 more insights

Risk Factors

  • • Sarbanes-Oxley Act compliance risk from failed internal control integration at acquisitions, e.g., Lima Acquisition, possibly causing material misstatements in financial reports
  • • Geopolitical risk from supply chain in China and Asia; political instability risks disrupting access to raw materials critical to manufacturing
+3 more insights

Get deeper insights on Enovis CORP

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available